SiNtx Technologies Inc (SINT) Quote

Agreed, but perhaps stockholders and industry would benefit most from an independent SiNTx. Too many divergent uses.
Thats a fair argument and the reason Sintx has to license the tech out. Its possible that a lack of independence is why Sonny hasnt moved forward on commercialization due to partner companies requiring concessions that might impact him eventually selling to Zimmer Biomet. That said, as those vulture funds attack from multiple angles theres no way to know if hes held back so they cant squeeze Sintx through a partner vs certain concessions. This would be a reason to not get a bank loan as those vulture funds can work the banks to squeeze Sintx making Sintx vulnerable from that angle. Its definitely a challenging position to be in.

One company could not manufacture products for all those industries. The issue with Sintx, at least atm, is it doesnt have access to the resources it needs to push development faster. Those holding this down are slowing development to the determent of society. I want Sonny to sell Sintx or its core IP to a much larger player that has the resources to push development faster. But not until SINT is properly valued so shareholders (including Sintx employees) also get a good return on investment.

========================================

Joe, im not trying to get you to invest. In fact i said your plan to wait until management invests to invest was very reasonable. We are debating the merits of Sintx as an investment going over the good and bad. We can both agree its a risky investment right now but at the very least it worth keeping an eye on/swing trade; although i think holding a small amount of shares long is a good, albiet risky, idea in case future rights offerings are extended. However we disagree on why its risky. You think management is a problem. I dont see management efforts to protect Sintx IP as bad. I see the conspiracy of hedge funds attacking Sintx/SINT as the problem. Im for Sonny protecting Sintx IP and for Sonnys continued effort to protect his shareholders investments from his efforts to protect IP to the best of his ability.

Agreed, but perhaps stockholders and industry would benefit most from an independent SiNTx. Too many divergent uses.

It's too bad that Vulture capital is keeping the company down.

We go through this often. First it doesn't matter at all IF I believe it. The truth is, I've seen plenty of companies with great potential get screwed over OR screw things up on their own. Imo, Sintx fits both. But, just for argument's sake, let's say I believe it all. I STILL wouldn't invest based on what I perceive and have always perceived and that is, poor management skills here. I'm sure I'm not alone. Anyway, enjoy the move upward. Looks like my prediction fell flat at least for this week.

Multiple companies should want to get their hands on Sintx IP dont you think? I only focus on Zimmer Biomet because its had someone in the leadership position at Sintx since its founding and has clearly tried to develop a hip implant with Sintx over the years.

2007 (ORS Annual Meeting Feb 11-14)

THERMAL CONDUCTIVITY OF FEMORAL BALL STRONGLY INFLUENCED UHMWPE WEAR IN A HIP SIMULATOR STUDY
Ten 28 mm ID isostatically moulded UHMWPE liners were investigated: GUR 1050 resin, gamma-sterilized with 25ñ40 kGy in argon (ArComô, Biomet Inc, Warsaw, IN). The liners were coupled with zirconia (Y-ZrO 2 : ProzyrÆ), cobalt-chrome (Biomet, Inc), silicon nitride (Si3 N 4 : Amedica-Inc, UT) and alumina femoral balls (Al2 O 3 : Biolox-forteÆ) (Figure 1).
Acknowledgements The authors thank Amedica, Utah, US and Biomet Inc, US for their support.
http://c.eqcdn.com/_5c7526ae538a6086a4025ef13f5136d2/amedica/db/265/660/pdf/0278.pdf

Joe, do you believe these two things to be factual?

Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn

Total = $324.36bn
Can Sintx not participate in all of the above markets?

Is the material better than every other material on market for ortho as indicated in the study below?

If the answer is yes to both those questions then Sintx IP is clearly worth waaaaaayyy more than the companies currently valued for. Sonny doesnt need to "sell" that the company is worth way more than it is, Zimmers acquisition of Implex already proves it is. He needs to prove that its IP is as good as i think it is. Then show he has a path to market with various strategic partners.

========================================

Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

accidental duplicate....

boston knows what they are talking about.....

Factually correct and well informed.

The statement appears to be correct and true to me.

These are risk-averse companies that look to smaller companies like us to develop an idea, uh, and, uh, de-risk it, so to speak, and then buy that technology.
J&J has a policy of depending on small companies to develop tech and then acquire that tech. Its been confirmed Zimmer BIomet stopped in-house development of spine well before divestment of spinal assets. Maybe it too is depending on small companies to develop tech and then acquire it.

So I think, the underlying concern that we had with our portfolio was we haven't innovated since the acquisition of LDR, and we needed to continue to innovate the portfolio specifically to Mobi-C. So there's a couple of things we're doing there.
In Figure 1, you can see J&J makes most of its money from pharmaceuticals and medical devices. They have grown these two sectors over the past decade through major capital investments in acquisitions and people development. Instead of investing in developing technology in-house, they use their size to acquire smaller companies who they believe have a promising trajectory in the healthcare space.

What are strategic alliances?

Strategic alliances, also known as strategic partnerships, are long-term, multi-department commitments with clearly defined goals for both companies. They differ from acquisitions and joint ventures because the companies remain separate entities (like how Starbucks and Target work together, within their own boundaries). However, strategic alliances have been known to lay the groundwork for acquisitions. But more on that later.

Quote Sources:

https://web.archive.org/web/20240408152758/https://sintx.com/wp-content/uploads/2021/03/Investor-Call-Transcript-033021.pdf
https://www.fool.com/earnings/call-transcripts/2023/11/02/zimvie-zimv-q3-2023-earnings-call-transcript/
https://d3.harvard.edu/platform-rctom/submission/a-family-of-companies-johnson-johnson/
https://insider.crossbeam.com/resources/strategic-alliance-definition-types-examples

========================================

Section 2 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

Zimmer/Biomet have been partners with Sintx on/off since before 2007 as shown in these posts which we both know youre aware of. Plus it hired a Si3n4 coatings expert to close out 2018 indicating its still interested in the IP. Why wouldnt it be considering the all scientific studies to date show its superior to other so called "biomaterials"?

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053136
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053353

You are also aware of a post from 2011 where it was claimed that Zimmer was interested in acquiring Sintx IP for licensing and Hip/Knee. For which both Sintx and Zimmer Biomet pursed a study of Sintx femoral head articulating against Biomet's liner. Again this you already know. You are also aware that madg lied about Zimmer Biomets strategic partnership with Sintx and how he downplayed the sharing of IP between the companies back then. Yet you discount this? Proof of strategic partnership is in Section 3 of this post.

As to why M&A hasnt happened yet lets look at two quotes that could explain it from both Zimmer Biomets perspective and Sintx:

Quote #1 is from a conference call in 2021. This quote indicates that Zimmer would be waiting for the IP to be sufficiently de-risked. Keep in mind that when i thought Zimmer Biomet was going to acquire Sintx in 2018, its IP was about to undergo a massive expansion which i was not aware of beginning in 2019. In fact, it can be argued that Sintx selling its implant patents was part of it getting ready for eventual acquisition by Zimmer Biomet as it was indicated that Zimmer intended to bring in revenue through licensing Si3N4 to other companies; specifically in spine. After 2018 sell of assets, Sintx switched to a licensing model for the bulk of its revenue.
These are risk-averse companies that look to smaller companies like us to develop an idea, uh, and, uh, de-risk it, so to speak, and then buy that technology.

As to why Sintx wouldnt be ready to sell itself yet, lets look at a quote from Amylin about why it wasnt ready to sell to Eli Lilly in 2009:
In a letter to Icahn made public in a filing with the Securities and Exchange Commission, Amylin's lead independent director, James Wilson, said Amylin believes a sale right now would "dramatically undervalue" the company.
As ive said and if anyone is interested, research Amylin Pharmaceuticals and its longstanding relationship (since founding) with Eli Lilly and compare that to Sintx and its relationship to Zimmer Biomet/Centerpulse since it was founded. Alot of the arguments you use against management is the same stuff Icahn laid out against Amylin's board. Despite hedge fund activist Icahn pushing a sale in 2009, Amylin wasnt acquired until 2012 which is likely when Eli would have acquired it had things been allowed to progress naturally. Despite Eli Lilly not acquiring Amylin in the end, i believe the whole Icahn thing was a ruse for the public and that Eli & Bristol Myers made a behind the scenes trade with Eli acquiring Bristol partner ImClone in 2008 & Bristol acquiring Amylin in 2012. Thus i believe its possible that Zimmer Biomet could do something akin to that in the end for its benefit. Although that seems less likely.

I'll add that Zimvie, a company that was made up of divested Spine/Dental assets, just completed its divestment of spinal assets to a hedge fund for less than 1x revenue Q1 2024. Suggesting that Zimmer Biomet and thus Zimvie is clearing outdated IP before acquiring new IP to take its place. Something it may have needed to do to maximize benefit for its shareholders. It was odd that Zimmer Biomet would divest IP that could be used in 15 billion in markets it could participate in the overall 64 billion ortho market unless it intended on eventually replacing the IP with something better. Especially when considering Zimmer Biomet is trying to diversify its IP portfolio and that move did the opposite making it more dependent on Hip/Knee markets. If there is another pandemic Zimmer Biomet will be the hardest hit of the 5 major ortho companies as its the only one not diversified outside of the ortho market.


As i already indicated, using the term gamer in reference to Ansons and other sharks in the billion dollar hedge fund category is misleading as it does not properly give weight to the legal/illegal methods they pursue to achieve their end result. Most gamers simply exploit a situation and move on. Ansons and Icahns arent just gamers they both function as activists investors and at least in Ansons case try to strip companies of their assets and toss them aside when done.

Quote Sources:
https://www.reuters.com/article/us-amylin-sb-idUSTRE53J5NU20090420/
https://web.archive.org/web/20240408152758/https://sintx.com/wp-content/uploads/2021/03/Investor-Call-Transcript-033021.pdf

========================================

Section 2 - A conspiracy of shorting and distorting.

This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174693152

This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174696175

According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as its been after Sintx IP for going on a decade. The following post goes into how much the company should be valued, methods used to protect IP, and sheer product addressable market size of over $320 billion.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174725108

========================================

Section 3 - Strategic Partnership

A basic roadmap laid out of Zimmer's intentions for Sintx back in 2011. This quote predates Sintx vast IP portfolio expansion. Any markets Zimmer Biomet does not currently participate in, that Sintx does, represents potential markets Zimmer Biomet can utilize Sintx to bolster its revenue through licensing as well as diversify those revenue sources.
AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.

Proof Zimmer Biomet is one of Sintx strategic partners:

Sintx 2016 10k

Together with a strategic partner, we have initiated biomechanical testing of our solid silicon nitride femoral heads. The results of this test will be released in 2017
This quote indicates the results of testing of their femoral head with a strategic partner will be released in 2017.
Those results were released testing Sintx Femoral head against Biomet's E1 liners. Thus Zimmer Biomet, or any of its subsidiaries, is Sintx strategic partner in this testing.

Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research
These are risk-averse companies that look to smaller companies like us to develop an idea, uh, and, uh, de-risk it, so to speak, and then buy that technology.

Quote Sources:

https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1
2016 10-k pg 13: https://www.sec.gov/Archives/edgar/data/1269026/000149315217010752/form10-k.htm
2017 results: https://ir.sintx.com/news-events/press-releases/detail/95/amedica-announces-results-of-independent-femoral-head-wear
https://web.archive.org/web/20240408152758/https://sintx.com/wp-content/uploads/2021/03/Investor-Call-Transcript-033021.pdf

========================================

Section 4 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

I use the term 'gamers' loosely. I consider a gamer basically ANYONE legal or illegal whose only interest is making money regardless who or what it ruins. I have no opinion on Icahn other than he's exceptionally smart and at least at times tells a company correctly, what it needs to do. After all, he IS an investor and wants a decent return. I don't remember whether or not it was he who jumped all over Hanes (hbi), but it's working....at least a bit.

My 'sell' comment was meant to sell to the public or private why the company should be valued at such and such and thus deserves a much higher share price (valuation); not to literally sell the company to a literal buyer.

I simply don't know if this is true or not. You have been wrong before but you make statements like the one below, as if it is a given. If so, I think it's not dumb to wonder if true, then why isn't it happening or has happened already? I believe it was madg who called you out on some supposed buyout years back but never materialized.

Joe, why is it you dont acknowledge that Sonny can sell Sintx IP to Zimmer oneday and give shareholders a sizable return?

Bal figures the best way out is to NOT communicate and NOT sell the company to potential investors
You said sell the company to potential investors which i took as meaning sell the company. Sell, not simply drum up interest for investment like its most recent PR indicated it was already doing.
Anson and its family of hedge funds are not gamers. They are professional sharks who not only make money with predatory offerings but also work as active investors to acquire targeted assets working as active investors. Would you refer to Icahn as a gamer? Even if you werent referring to them as potential investors you're still downplaying what they do. They dont just exploit situations for profit they attack companies to acquire them and profit. In Sintx case i suspect they are working as a front for other interests.
They have been accused of attacking companies on multiple fronts to weaken them.

Catalyst Capital files $450-million lawsuit accusing Anson Funds, West Face of short-selling 'conspiracy'
Lawsuit claims ‘Wolfpack Conspirators’ worked with group of borrowers who had defaulted on loans to Callidus

The lawsuit, filed Tuesday in Ontario’s Superior Court of Justice, claims the group targeted Callidus with a short-selling strategy that involved coordinating with and providing financial support to a group of borrowers who had defaulted on loans to Callidus, and were fighting to prevent Callidus from collecting.

It also alleges use and attempted use of the news media to further their short-selling campaign, improper use of a new regulatory whistle-blowing program, and coordinated buying and selling of shares.

None of the allegations have been proven in court.
https://financialpost.com/news/fp-street/catalyst-capital-files-450-million-lawsuit-accusing-anson-funds-west-face-of-short-selling-conspiracy

========================================

Joe, why is it you dont acknowledge that Sonny can sell Sintx IP to Zimmer oneday and give shareholders a sizable return? Your advocation of his removal impedes such a possibility which seems odd if you only care about shareholders ROI. Criticism is fine but things like this deserve acknowledgement. Just like Sonny attempts to protect his investors with full ratchet anti-dilution clauses.

========================================

Section - A conspiracy of shorting and distorting.

This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174693152

This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174696175

According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as its been after Sintx IP for going on a decade. The following post goes into how much the company should be valued, methods used to protect IP, and sheer product addressable market size of over $320 billion.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174725108

========================================

Section 4 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

You gotta know how it fows...

Don't know where you got that. I'm not talking about gamers, but rather those (honest investment firms/ institutions/ individuals) who would LOVE TO see what you see IF Sonny and gang were more (let's say) aggressive in their sales pitch, promoting the attributes of Sint and what it has to ACTUALLY OFFER as a company.
Joe, you claim to not be part of the wolfpack but you just described the entities attacking SINT as simply potential investors.As I've said over and over again, the gamers look to take advantage and Sonny gives them a lot of room to do just that.

Sonny has a duty to his stakeholders which includes the community at large; the end user, the surgeons, the OR nurses and other staff that assist, hospitals, the sales reps, etc.. If Si3n4 is the best implantable material right now, as indicated in the study in section 3 of this post, then its his duty to make sure that whomever acquires the tech brought it to market in the most expansive way possible. Thats the biggest issue with "investors" or hedge funds acquiring the tech. You do not know for certain if those investors will sell the IP to companies that will bring the tech to market or just sit on it to make sure no one else brings it to market. Thats all hedge funds do, acquire tech cheap and resell for a significant profit. If its the latter, then the entire community suffers. Even if they do sell to companies that will bring the material to market, will they license the tech like Zimmer Biomet plans to? Thats what would be best for the community stakeholders, whichever company acquires the tech, makes sure the tech is licensed to as many companies within every industry Si3n4 can be used in as possible. This way the material reaches maximum penetration potential and all those involved benefit.

So Sonny is task with not only maximizing shareholders return, which wouldnt be much of a return unless an offer exceeds $230m, but also to see the global community receives max benefit as well. This is why i support Sintx being acquired by Zimmer Biomet one day because i believe its intentions are the most pure based on the evidence ive collected to date. Its been behind and supporting Sintx since at least 2005 when Sonny first became a surgeon consultant for Sintx in addition to his work with Zimmer then.

I guess Bal figures the best way out is to NOT communicate and NOT sell the company to potential investors
Joe, you claim to not be part of the wolfpack but you just described the entities attacking SINT as simply potential investors. That puts them in a much more favorable light than their actions to date suggest; evidence over rhetoric.
If their intentions were mostly pure, they wouldnt be working in the shadows and then blaming management for their misdeeds. Thats your first clue they are mostly self serving. They also wouldnt being trying to weaken Sintx to the point that its forced to sell at significant discount compared to the IPs worth screwing over employees and shareholders. Further supporting their self serving nature. Lastly they would not try to sabotage Sintx bringing products to market because that hurts the community at large more than Sintx; i cannot prove this but these hedge funds have done this to other companies theyve targeted according to lawsuits. Again showing that they are not simply investors trying to right this ship.
If they wanted to win me over they would need to show an actual plan to get the products to market in a safe and timely fashion to as many people as possible in a way that is superior than what little we know of Zimmer Biomets plans. Otherwise, based on behavior to date, im going with the default opinion they are only out to make a buck while screwing everyone else.

One can blame the shorts and manipulators but EVERY company has to deal with adversity and figure a way out.
Thats indeed true. Every company has to deal with adversity and figure a way out, which Sonny has to do. However showing that these hedge funds are attacking SINT in a hostile fashion takes away basher narrative that management is corrupt, screwing shareholders, and is instead defending the company while trying to protect shareholders investment to date. It also helps explain Sonny's actions instead of leaving them open to being spun in a negative manner. Context and understanding whats really going on is key. Im not saying i grasp everything thats going on but i do want to understand and i depend on evidence over rhetoric to do so.

========================================

In 2011 the following quote was posted to the spineblogger blog:

AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.
If you analyze Sintx moves to date and its transition from implant sales to OEM/licensing model, you'll see that quote is still very much correct. This quote and Zimmer Biomets support of Sintx over the years, is why i think Zimmer Biomet is the best entity to acquire Sintx IP oneday. Without evidence indicating otherwise, Zimmer Biomet acquisition of the IP oneday, for a sizable sum, is the best thing for shareholders and community stakeholders.

https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1
========================================

Section 3 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

I have cut down. I do wonder why I even watch this stock, to be honest. It's all too familiar; Sonny's in yet another dire situation (as usual) due to his great communication skills. He needs money fairly soon and no one is interested in buying stock. NO ONE! And now he's got to figure out a way to drum up interest, while not bringing the stock down too much. The question is, when does he begin? One can blame the shorts and manipulators but EVERY company has to deal with adversity and figure a way out. I guess Bal figures the best way out is to NOT communicate and NOT sell the company to potential investors; not to mention, he also doesn't have a concurring thought on any matter concerning the running of the business. It is what it is......

TA, i do not receive shares to post. I do however receive the same share round up treatment every other shareholder receives. Even the hostile funds get their shares rounded up.

Fractional Shares

Our stockholders will not receive fractional post-Reverse Split shares in connection with the Reverse Split. Instead, any fractional shares that would otherwise be issuable as a result of the Reverse Split will be rounded up to the nearest whole share. No stockholders will receive cash in lieu of fractional shares.
If management were to issue shares to purchasers like me that oppose a hostile takeover, that also does not qualify as shares for posting because other shareholders would receive the same treatment. Not every shareholder obviously, but the ones that oppose a hostile takeover as spelled out in the DEFN14A.

https://www.sec.gov/Archives/edgar/data/1269026/000149315224014753/formdefn14a.htm#da_007

Fourthly, reverse stock split can help companies prevent hostile takeovers and protect their shareholders. By reducing the number of outstanding shares, companies can make it more difficult for hostile acquirers to accumulate a controlling stake in the company. This can protect the interests of the existing shareholders and prevent the company from being taken over at a low price.
Combine this with the following and its further evidence of hostile entities behind the scenes trying to acquire Sintx cheap but likely above current market value (already absurdly low). However if Sonny sold to Zimmer at a later date, he could unlock much higher ROI for him and his shareholders. Thus its in shareholders interest to align with this goal.

The increase in the number of shares of authorized but unissued and unreserved Common Stock will have an “anti-takeover effect” by permitting the issuance of shares to purchasers who might oppose a hostile takeover bid or oppose any efforts to amend or repeal certain provisions of our Charter. The increased number of available authorized but unissued shares of Common Stock as a result of the Reverse Split would give the Company’s management more flexibility to resist or impede a third-party takeover bid that provides an above-market premium that is favored by a majority of the independent stockholders.

Quote Sources:
https://fastercapital.com/topics/advantages-of-reverse-stock-splits-in-mergers-and-acquisitions.html
https://www.sec.gov/Archives/edgar/data/1269026/000149315224014753/formdefn14a.htm

=======================================

Section 2 - Here are all the anti-takeover provisions employed at Sintx.

1. Poison pill aka Shareholder Rights Plan

2. Staggered Board

3. Shark Repellant - requiring supermajority vote

4. Golden Parachute for management

5. Crown Jewel Defense - CTL has first rights to acquire Sintx IP.

6. CTL is setup as a White Knight via its first rights to acquire Sintx IP.

7. If Sintx sold its main IP to CTL thats effectively scorched earth as Sintx has little value, in comparison, without its patent portfolio. Sintx would still have TA&T & Sintx Armor for value in the event it had to sell its core Si3n4 IP to CTL, even if for a short time. That would be a reason to keep Armor division.

========================================

Section 3 - A conspiracy of shorting and distorting.

This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174693152

This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174696175

According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as its been after Sintx IP for going on a decade. The following post goes into how much the company should be valued, methods used to protect IP, and sheer product addressable market size of over $320 billion.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174725108

========================================

Section 4 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

Regardless Joe all your posts benefit the wolf pack and conspiracy of funds because they are always negative with little balance. Thats the essence of a stock basher regardless of what you say. Madg said for years he didnt believe/Zimmer Biomet wasnt Sintx partner and downplayed the sharing of Ip like it wasnt indication of a strategic partnership. That tuned out to be a blatant lie because its in the 10k which he read, at least back then, more extensively than I. I bring that up because i didnt think you guys would blatantly lie like that. Usually its some truth and deception or sarcasm to avoid confirming or denying.

Some of your criticisms are warranted but most are exaggerated like your comments about masks. Furthermore most of your criticisms are really only about the stockprice and most of thats due to the conspiracy of funds shorting and distorting here; as well as Sonny's attempts to keep them from acquiring larger positions (excessive dilution and RS). With that knowledge you should have softened up on bashing management for the stocks performance. If you are not a basher, than why arent your posts more balanced? Why is it you do not acknowledge the positives while also highlighting the negatives management can control? Why with the knowledge of a short and distort conspiracy is your rhetoric the same?

The only thing we seem to agree on is the IP is worth alot. Although in your eyes more so with different management (how much is harder to determine). Secondly Sonny is slow to commercialize products. However with Sonny's connections to Zimmer Biomet and its interest in Sintx IP, something you do not acknowledge, Sonny can, eventually, generate large returns for investors which you claim to be all about. Thus you should be more bullish on Sintx than your posts indicate. For now all Sonny can do for his long term shareholders is provide them with full rachet anti-dilution protection until he can begin to unlock the value Sintx is sitting on.

========================================

A basic roadmap laid out of Zimmer's intentions for Sintx back in 2011. This quote predates Sintx vast IP portfolio expansion. Any markets Zimmer Biomet does not currently participate in, that Sintx does, represents potential markets Zimmer Biomet can utilize Sintx to bolster its revenue through licensing as well as diversify those revenue sources.
AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.

Proof Zimmer Biomet is one of Sintx strategic partners:

Sintx 2016 10k

Together with a strategic partner, we have initiated biomechanical testing of our solid silicon nitride femoral heads. The results of this test will be released in 2017
This quote indicates the results of testing of their femoral head with a strategic partner will be released in 2017.
Those results were released testing Sintx Femoral head against Biomet's E1 liners. Thus Zimmer Biomet, or any of its subsidiaries, is Sintx strategic partner in this testing.

Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research
These are risk-averse companies that look to smaller companies like us to develop an idea, uh, and, uh, de-risk it, so to speak, and then buy that technology.

Quote Sources:

https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1
2016 10-k pg 13: https://www.sec.gov/Archives/edgar/data/1269026/000149315217010752/form10-k.htm
2017 results: https://ir.sintx.com/news-events/press-releases/detail/95/amedica-announces-results-of-independent-femoral-head-wear
https://web.archive.org/web/20240408152758/https://sintx.com/wp-content/uploads/2021/03/Investor-Call-Transcript-033021.pdf

========================================

Section 3 - A conspiracy of shorting and distorting.

This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174693152

This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174696175

According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as its been after Sintx IP for going on a decade. The following post goes into how much the company should be valued, methods used to protect IP, and sheer product addressable market size of over $320 billion.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174725108

In your book, the only thoughts about Sint and its lovely management team, must be positive (regardless its never-ending dismal performance over the years), otherwise it's bashing (with ulterior motives, of course).
Joe, you continue to post bash oriented material to the board.
I've said recently for the umpteenth time that I have no 'interest' in this stock whatsoever, other than I follow it (like a sick hobby, I guess), but of course that doesn't follow your preconceived never-changing views or narrative and so once again, you insinuate or assume. And once again, you're WRONG! May I suggest that you keep investing in order to keep your winning streak alive?
Trying to shake some shares loose are we?

Looks like Pitk17 is "distorting" SINT on other tickers to get other shorts attention to help short here since SINT seems to have support...at least until new shares hit market. Do you have some naked short position you hope to cover Pitk or are you one of those wolfpack individuals that trying to help Anson's family of funds with their short and distort conspiracy?

He did a name change for some reason:
https://stocktwits.com/BroadOne/message/580328150

Joe, you continue to post bash oriented material to the board. The offering is direct to market so anything can happen depending on the news its connected with. Trying to shake some shares loose are we? Regardless SINT remains significantly undervalued. Currently trading below IP value, book value, shareholders equity value, and cash value.
Can BOD and management even participate in ATM offerings? Also why would they participate when theres an ongoing short and distort campaign against SINT? They should be saving their investment for the right time if they want to prevent any type of hostile acquisition. Same reason for them to continue to get salary. If they took shares instead of salary that weakens their ability to defend SINT especially as Sonny continues to dilute and RS to prevent this conspiracy from acquiring too large of a position.

Markets Si3n4 can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn

Total = $324.36bn

Its honestly overwhelming the size of the markets Sintx material can be used in. Hypothetical scenario using 5% market penetration with a 5% licensing fee equates to $811m in yearly licensing revenue. Thus Si3N4 is worth at least $800m in potential yearly revenue for an acquiring company through licensing revenue according to this scenario. Its ability to penetrate the above markets will vary but Ortho & Catheter markets are markets that Si3N4 should significantly penetrate; with Wound Care & Dental being up there as well. Condom market is more hypothetical based on Si3N4 ability to kill Herpes and possibly other STI. However would need to be studied further to ensure it doesnt impact the delicate microbe balance inside a vaginal canal. A new patent was awarded Sintx for the use of Si3n4 against funguses that impact the wine industry providing yet another market it can tap into. This could be a market that they could break into sooner than some of the others listed above but it wouldnt be as lucrative.

Sources:
https://web.archive.org/web/2024040...ogger.blogspot.com/2011/05/whos-next.html?m=1
https://orthospinenews.com/2021/01/...y-2025-as-acquisitions-surge-says-globaldata/
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
https://www.mordorintelligence.com/industry-reports/armor-materials-market
https://www.grandviewresearch.com/industry-analysis/dental-implants-market

========================================

Section 2 - A conspiracy of shorting and distorting.

This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174693152

This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174696175

According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as its been after Sintx IP for going on a decade. The following post goes into how much the company should be valued, methods used to protect IP, and sheer product addressable market size of over $320 billion.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174725108

========================================

Section 3 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

My guess is one day this week, Sint will drop a ton (like 30 cents), planting them securely in the $4+ range. From there, Sonny will again release a timely redo of their previous offering. In the end I'm guessing $3+ range before he gets any takers. And of course, as usual, he and the bod will NOT participate. Only, in the bizarro world of Sint....

Correction: one of the offerings i had in Q2 happened end of Q1 and thus they should have $1.3m less. So ~$4.7m cash and thus $6.27 per share not $8.

I still estimate that Sintx accumulated deficit is worth at least $230m ($161 per share if OS grows to 1.42m). Thus any offer for Sintx must be over that.

Accumulated Deficit and Tax Write-off

Sintx Accumulated Deficit = $271.6m. For an acquiring company to utilize this for tax write off purposes Sintx IP would have to be valuable enough to bring in sufficient revenue. However as the cost to acquire Sintx would cost millions between accounting audits, lawyers, golden parachutes, etc.. Sintx accumulated Deficit would likely represent about the same value as what Implex was acquired for to an acquiring company. That is only if Sintx IP couldnt generate more revenue than Sintx deficit. The following will show that it can easily.
Also, acquiring Sintx for that amount would increase goodwill which is an asset the acquiring company can depreciate and thus provide additional tax benefit as well as increase its assets.


According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as its been after Sintx IP for going on a decade. The following post goes into how much the company should be valued, methods used to protect IP, and sheer product addressable market size of over $320 billion.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174725108

mrinvestorpro
9m
@BroadOne no it means a sale or partnership. They have $15 per share in cash. Not including their patents, technology or clients. They sell for $15+ you triple your money. Get a partner and u could get 10x your money on a run with that tiny float.
BroadOne = PitK17. Guess he decided to change his avatar for some reason. This MrInvestorPro makes good points except they do not have $15 per share in cash unfortunately. ~$6m in Cash end of Q1 with a burn of about $2.8m a quarter means they have about $6m cash at the beginning of Q3 after the funds raised in Q2 offerings. Thus $6m cash and OS of 750k thats $8 per share with a current stock price of $5.07 or so. Stockholders equity is about $13.00 per share right now. Stockholders equity does not factor in the value of Sintx IP. Hell its accumulated deficit is worth $300 per share right now.

I dont think they are looking to sell the entire company but could sell off an asset. Id rather a partnership or sell off Armor to NP Aerospace with licensing revenue. Regardless you can bet the hedge funds that are trying to acquire Sintx through hostile means will look to sabotage any such deals.

https://stocktwits.com/mrinvestorpro/message/580096417

========================================

Section 2 - A conspiracy of shorting and distorting.

This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174693152

This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174696175

According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as its been after Sintx IP for going on a decade. The following post goes into how much the company should be valued, methods used to protect IP, and sheer product addressable market size of over $320 billion.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174725108

========================================

Section 3 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

The increase in the number of shares of authorized but unissued and unreserved Common Stock will have an “anti-takeover effect” by permitting the issuance of shares to purchasers who might oppose a hostile takeover bid or oppose any efforts to amend or repeal certain provisions of our Charter.
Another anti-takeover measure, issuing more shares to holders of common stock that would oppose a hostile takeover by the conspiracy of funds mentioned in a previous post of mine. As you can see in the next section of this post, Anson and its family of funds often target companies with valuable assets, like Sintx, to try to acquire in a hostile fashion. Usually they go for board seats but they can do low ball offers. FYI: This language was not present in the previous RS.

https://www.sec.gov/Archives/edgar/data/1269026/000149315224014753/formdefn14a.htm pg 9.

========================================

According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as its been after Sintx IP for going on a decade. IP thats destined to take over the ortho industry according to one study linked at the bottom of this post.

Their playbook is simple: they find a promising company like Nano that has attracted significant investment, furtively acquire a large position, and then seek to dismantle the company and distribute its cash for Defendants’ own benefit.

https://www.sec.gov/Archives/edgar/data/1491072/000119312523131774/d264274dex993.htm

So Lets examine the value of Sintx and its IP here from a few angles. This should show exactly why Anson's family of funds would be trying to take over Sintx through hostile means. It represents alot of potential money for them if they can succeed. A work in progress.

Transitive Property:

In 2003, Zimmer acquired a materials company for $232m with $108m of it upfront and the remaining $124m coming over the next two years based on sales milestones. Before announcing its partnership with Zimmer, Implex had revenue about the same as Sintx should achieve this year. Its material Hydrocel, Trabecular Metal, could be used for multiple orthopedic implants. Spine, dental, hip, shoulder, and i think knee. That said, Trabecular metal cannot be used as a coating or imbued in materials like silicon nitride can to bring those materials its beneficial enhancements. Thus its market potential in the ortho/dental markets was smaller.

Thus Sintx valuation should be at minimum based on what similar companies are worth: $232m

Accumulated Deficit and Tax Write-off

Sintx Accumulated Deficit = $271.6m. For an acquiring company to utilize this for tax write off purposes Sintx IP would have to be valuable enough to bring in sufficient revenue. However as the cost to acquire Sintx would cost millions between accounting audits, lawyers, golden parachutes, etc.. Sintx accumulated Deficit would likely represent about the same value as what Implex was acquired for to an acquiring company. That is only if Sintx IP couldnt generate more revenue than Sintx deficit. The following will show that it can easily.
Also, acquiring Sintx for that amount would increase goodwill which is an asset the acquiring company can depreciate and thus provide additional tax benefit as well as increase its assets.

Potential Market Size

One particular thing about Sintx is its current sales represents a fraction of 1% of its potential revenue because it has not actually transitioned into the commercialization phase yet. The 99% of its products remain in R&D stage. Sort of like a pharma company.

Silicon Nitride increases osteointrgration, improves imaging, and is antimicrobial (antiviral, antibacterial, antifungal) while being bioactive and biodegradable. That means as it corrodes the material breaks down into materials the body can use. For instance in an aqueous solution, Si3N4 turns into orthosilicic acid which the body utilizes for bone growth. Unlike other materials used in orthopeadic implants, Si3N4 shouldnt accumulate in the body as it can be excreted. Meanwhile Titanium, Trabecular Metal, PEEK, ZTA, all accumulate in the tissue, blood and/or organs. Metals seem to spread through the body while other ceramics and plastics mostly accumulate locally. This is all important to understand when you consider that Si3n4 is destined to replace current materials used in the $64 billion ortho implant industry. As Si3n4 can be used as a coating for metal implants and can be imbued in PEEK materials, it could and should capture almost the entire ortho industry but only though partnerships and licensing.

Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn

Total = $324.36bn

Its honestly overwhelming the size of the markets Sintx material can be used in. Hypothetical scenario using 5% market penetration with a 5% licensing fee equates to $811m in yearly licensing revenue. Thus Si3N4 is worth at least $800m in potential yearly revenue for an acquiring company through licensing revenue according to this scenario. Its ability to penetrate the above markets will vary but Ortho & Catheter markets are markets that Si3N4 should significantly penetrate; with Wound Care & Dental being up there as well. Condom market is more hypothetical based on Si3N4 ability to kill Herpes and possibly other STI. However would need to be studied further to ensure it doesnt impact the delicate microbe balance inside a vaginal canal. A new patent was awarded Sintx for the use of Si3n4 against funguses that impact the wine industry providing yet another market it can tap into. This could be a market that they could break into sooner than some of the others listed above but it wouldnt be as lucrative.

In Summary, you can see that Sintx has extremely valuable IP that can be used in markets that are cumulatively in the hundreds of billions in size. That is why Anson and the other family of funds its connected to would want to get their hands onto that IP. Like Nano, it looks like this conspiracy of funds was getting ready to make a move before I exposed them with three of the funds accumulating a position this year. However recent offerings by management seems to have helped in diluting their positions to prevent a similar situation to Nano as shown in the first of these three posts.
Because Sonny has employed several methods of protection to protect Sintx IP from hostile entities, their only option to get the IP is hope they can drive Sintx into bankruptcy as Sonny has setup crown jewels defense in the event this group attempts a hostile takeover. As Sintx has no debt, Sonny and then board cannot be forced into selling the IP to a particular entity. Upside to Sintx not having loans and likely a big reason it has not obtained one so since Hercules loan in 2014.

4/01/2024 L1 Capital Global Opportunities Master Fund, Ltd.
https://www.sec.gov/Archives/edgar/data/1269026/000107997324000472/0001079973-24-000472-index.htm
Notice that on April 1st, L1 filed its 13G indicating it had 8.8% of outstanding stock. Two days later, Sintx announces an offering at 2.1 cents adding 71m shares of stock.

(2) Based on 51,080,139 shares of Common Stock outstanding as reported in the Issuer’s filings with the Securities and Exchange Commission.
Once this offering completed, L1 stake in Sintx became 3.6%.

This indicates that Sonny is not simply raising funds, but that hes preventing these funds from accumulating too large of a position (Poison Pill type offering?). Thus this game of massive dilution and reverse splits seems to be a game of Sonny defending Sintx from this group of hostile funds as well as raising needed funds. As long as this group of funds continue to attempt to take over Sintx through hostile means, we can expect this to continue. However with Nasdaq putting Sintx on probation for a year, it's limited on its ability to raise funds while diluting this groups position as it must stay over $1. This has likely prompted the recent new of Sintx exploring strategic opportunities.


Sources:
https://web.archive.org/web/2024040...ogger.blogspot.com/2011/05/whos-next.html?m=1
https://orthospinenews.com/2021/01/...y-2025-as-acquisitions-surge-says-globaldata/
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
https://www.mordorintelligence.com/industry-reports/armor-materials-market
https://www.grandviewresearch.com/industry-analysis/dental-implants-market

=======================================

Section 3 - Here are all the anti-takeover provisions employed at Sintx.

1. Poison pill aka Shareholder Rights Plan

2. Staggered Board

3. Shark Repellant - requiring supermajority vote

4. Golden Parachute for management

5. Crown Jewel Defense - CTL has first rights to acquire Sintx IP.

6. CTL is setup as a White Knight via its first rights to acquire Sintx IP.

7. If Sintx sold its main IP to CTL thats effectively scorched earth as Sintx has little value, in comparison, without its patent portfolio. Sintx would still have TA&T & Sintx Armor for value in the event it had to sell its core Si3n4 IP to CTL, even if for a short time.

========================================

Section 4- A conspiracy of shorting and distorting.

This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174693152

This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174696175

========================================

Section 5 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

Sonny needs to do something to increase valuation, and keep it elevated, as SINT current market valuation is a mere $3.7m. If the OS jumps to 1.4m thats around $2.8 price per share to maintain that $4m valuation. $5.7 equates to $8m valuation at 1.4m OS. Despite multiple pieces of good news nothing seems to allow valuation increase over $4m for long. Even an up to $8m aerospace contract over a 10 year period didnt help increase valuation. Of course those shorting and distorting here arent going to allow the price to increase for long.
$4m valuation is over a 50% discount from stockholders equity.

Valued at potentially as much as $8 million over the life of the agreement, the LTA represents the single largest customer agreement to date for SINTX. The LTA incorporates a significant commitment from SINTX to collaborate with their customer on reducing costs, improving efficiencies, and implementing productivity programs. The LTA extends to the end of 2034 with a customer option to renew for an additional 10-year period.
https://ir.sintx.com/news-events/press-releases/detail/223/sintx-technologies-enters-into-a-second-long-term-supply

Exposing Market Manipulation tactics:
https://fastercapital.com/content/Market-Manipulation--Exposing-the-Tactics-of-Stock-Bashers.html#Common-Tactics-Employed-by-Stock-Bashers
https://www.ethosdebate.com/lies-rhetoric-4-18-rules-disinformation/

========================================

Section 2 - A conspiracy of shorting and distorting funds and their wolfpack.

This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174693152

This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174696175

According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as its been after Sintx IP for going on a decade. The following post goes into how much the company should be valued, methods used to protect IP, and sheer product addressable market size of over $320 billion.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174725108

========================================

Section 3 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

This is something Sonny has done for shareholder, or true stakeholders, of Sintx.

Unless otherwise indicated, the information in this prospectus supplement, including the number of shares outstanding after this offering, does not reflect:
? the effect of the “full-ratchet” anti-dilution adjustment of the conversion price of our outstanding Series B Convertible Preferred Stock and the exercise price of our outstanding October 2022 warrants.
As the stock price decreases so too does the conversion prices of these Series B preferred and October 2022 warrants. I have the latter as i participated in the 2022 shareholder rights offering. Current conversion of Series B from '20 and Oct '22 warrants is $4.2. Are those shorting and distorting here going to lower my conversion price further? Either way i win. Price goes up i can make money. Price goes down it reduces the cost of conversion (cost basis) for when this eventually goes waaaayyy up (assuming Sonny prevails).
The October 2022 warrants are exercisable at an exercise price of $4.20 per share. The Series B convertible preferred stock and October 2022 warrants contain full-ratchet anti-dilution provisions which, subject to limited exceptions, would reduce the conversion price of the Series B preferred stock (and increase the number of shares issuable under the Series B preferred stock) and reduce the exercise price of the October 2022 warrants in the event that we in the future issue common stock, or securities convertible into or exercisable to purchase common stock, at a price per share lower than the conversion price or exercise price then in effect. Depending upon how such provisions are interpreted, the alternative cashless exercise provision contained in the Class C Warrants and Class D Warrants could potentially result in a significant reduction in the conversion or exercise price of the Series B convertible preferred stock and October 2022 warrants.
My preferred shares from the 2022 rights offering are essentially worthless, outside of loss harvesting, right now because of the Reverse splits. However its possible that in future rights offerings i'd be allowed to exchange current preferred for new offering units at much more favorable conversion price. This was done for holders of units from before Sintx went public. Investors like Sonny were able to exchange their old preferred for new units.
This goes against the narrative management doesnt care about its stakeholding (true long) shareholders and hasnt done anything to protect their investment while Sonny battles hostile funds attacking SINT.

In regards to the CEO's bonuses, Sonny deserves them for the sheer value hes created to Sintx IP over his time as CEO. Sintx went from being able to potentially sell products in a $64 billion dollar ortho implant and $5 billion dental industry , to now having potential products that could participate in industries that exceed $300 billion in size; this being a major reason this family of funds would be trying to seize Sintx through any means it can. So yes $50k bonuses is cheap for that level of accomplishment. He deserves larger bonuses but Sintx cannot afford that until he actually starts commercializing some of those products. When he, or his successor does, then shareholders might finally start to get a return on their investments over the years. Until then this remains insanely cheap valued at only $3.9m while being risky due to those hostile funds.

Quote Source:
https://www.sec.gov/Archives/edgar/data/1269026/000149315224026958/form424b5.htm

========================================

Section 2 - Potential Market Size

One particular thing about Sintx is its current sales represents a fraction of 1% of its potential revenue because it has not actually transitioned into the commercialization phase yet. The 99% of its products remain in R&D stage. Sort of like a pharma company.

Silicon Nitride increases osteointrgration, improves imaging, and is antimicrobial (antiviral, antibacterial, antifungal) while being bioactive and biodegradable. That means as it corrodes the material breaks down into materials the body can use. For instance in an aqueous solution, Si3N4 turns into orthosilicic acid which the body utilizes for bone growth. Unlike other materials used in orthopeadic implants, Si3N4 shouldnt accumulate in the body as it can be excreted. Meanwhile Titanium, Trabecular Metal, PEEK, ZTA, all accumulate in the tissue, blood and/or organs. Metals seem to spread through the body while other ceramics and plastics mostly accumulate locally. This is all important to understand when you consider that Si3n4 is destined to replace current materials used in the $64 billion ortho implant industry. As Si3n4 can be used as a coating for metal implants and can be imbued in PEEK materials, it could and should capture almost the entire ortho industry but only though partnerships and licensing.

Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn

Total = $324.36bn

Its honestly overwhelming the size of the markets Sintx material can be used in. Hypothetical scenario using 5% market penetration with a 5% licensing fee equates to $811m in yearly licensing revenue. Thus Si3N4 is worth at least $800m in potential yearly revenue for an acquiring company through licensing revenue according to this scenario. Its ability to penetrate the above markets will vary but Ortho & Catheter markets are markets that Si3N4 should significantly penetrate; with Wound Care & Dental being up there as well. Condom market is more hypothetical based on Si3N4 ability to kill Herpes and possibly other STI. However would need to be studied further to ensure it doesnt impact the delicate microbe balance inside a vaginal canal. A new patent was awarded Sintx for the use of Si3n4 against funguses that impact the wine industry providing yet another market it can tap into. This could be a market that they could break into sooner than some of the others listed above but it wouldnt be as lucrative.

========================================

Section 3 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

This is essentially how the wolfpack operates around offerings. They naked short before the offering via one fund and then one or more of the other funds buy the offering and they use those shares to cover the the naked short position of funds not participating in the offering. At first i thought this how how they circumvent SEC rules that prevent a fund preshorting an offering like this. However it seems that if funds collectively own more than 10% of the offering/outstanding shares, then they are illegally pre-naked shorting offerings in addition to trading on inside information. If they naked shorted last week, id think they'll be wanting to get people to sell their shares to cover those naked short positions if Sonny delays releasing new shares to market. So watch for posts that over-exaggerate managements lifestyle, pay, or anything "negative".

Here is a trade that is almost guaranteed to make money, though it is also double super illegal.

These companies -- there were 13 of them, all pretty small -- raised money through what the SEC calls "confidentially marketed public offerings." A company would engage an investment bank, which would call up potential investors and ask if they wanted to buy shares in the company. The bank would do this before the company publicly announced the offering, and would "wall-cross" the potential investors, making them agree to keep the information about the offering secret until it was announced publicly.
So here's a predictable stock-market pattern and an easy way to exploit it: If a company calls you up to ask you to invest in its upcoming public offering, you should (1) say yes, (2) sell the company's stock short before the public announcement, and then (3) buy the stock back in the public offering, generally at a 10+ percent discount, a few days later.

This is of course not legal advice! It is a great trade, but it is also double super illegal, insofar as:

There is a specific SEC rule against short selling stock just before a public offering and then buying back the stock in the offering, 5 and
There is a general, and much more important, rule against trading on purloined material nonpublic information, and this is that.


trading in breach of that agreement, you are clearly violating not just the contract, but also insider trading laws, which make it illegal to trade "in breach of a fiduciary duty or other relationship of trust and confidence, while in possession of material, nonpublic information about the security."

But, you know, who will check?
Some of the funds would get wall-crossed, and then they'd tip each other and trade in the other funds to try to obscure what was going on:
When they were successful in obtaining such information, Fishoff shorted the issuer’s stock in advance of the offerings, directed trading by Chernin and Costantin in those instances when he did not place the trades on his own, and tipped Petrello, who then also shorted the stock through Brielle and Oceanview.

In many instances, the Fishoff-controlled entities for which Chernin and Costantin were fronting also participated in the offering, with the stock going to Featherwood’s account and often being used to cover the short sales.
This right here is most likely how this family of funds worked. 1+ of them would get information of a forthcoming offering which it would later participate in, and tip the others off so they can pre-short. Not sure why the author says pre-short, wouldnt this be naked shorting? They then used the shares from the offering that Fund #1 received to cover those naked short positions?

By cheating on their wall-cross agreements and shorting the stock, these guys had the effect of driving down the stock price, which probably reduced the price in the offering. These companies probably got less money for their stock because their nonpublic information was (allegedly) used against them.
Though you could have a more cynical view of this sort of thing. A company needs to sell stock, but worries that announcing a public offering will drive down its stock price and not produce any takers. So it calls some investors up privately and tells them it's doing a deal. Those investors agree to invest in the deal, but before the deal is announced they lay off their risk by shorting the company's stock. Then the deal is announced and the investors buy shares from the company to (illegally) cover their shorts. The investors get their 10 percent, or whatever, discount to the market price as a commission; their real function is not to invest in the deal but to intermediate between the company (which can't sell stock without a publicly disclosed offering) and the unsuspecting public (which buys from the "investors" before the public disclosure). The wall-cross agreement creates deniability for the company. No one's stealing from the company; they're helping the company get a deal done that would otherwise be much harder to achieve. The victims are the public who buy from the insider traders at the inflated, pre-announcement price.
There is definitely evidence supporting this, especially between 2022 RS & 2024 RS. For instance, Lind Group participated in the offering, these funds naked shorted from as high as .50s before Lind used their shares to cover those shorts at .15. Thus this group of funds "laid off their risk", making millions in a few days, and did in fact work as an intermediary between the company and the public as they dumped shares. Lind Group sold off its shares in a matter of days. This group of investors gets a hell of alot more than 10% off these offerings. After factoring in the 200:1 split theyve been shorting since 100 with a hell of a pump and dump between .04 to .22 pre-split (8-44 post split).

You short 16 million, knowing once the offering price is announced, the stock will take a hit. Voila, in 24 to 48 hours you just made 1.6 million by buying back at .15 +
Fund A would be the one that bought the offering, in this case Lind Group. Funds B, etc.. (theres like 9 funds identified so far) would be the ones naked shorting like described here by Joev2. For which i replied:
Its the hfunds that made the $1.6m you describe. Also they NAKED shorted on news of the R&D contract with the army, thus they NAKED shorted from .25-.50 range making alot more than the $1.6m you mentioned. If every .1 represents $1.6m profit then if they have an average Naked short position of .35 then that translates to $3.2m in 24 to 48 hours. Essentially funding the offering in 1-2 day period.
They announced the news on Jan 30th when these funds pre-naked shorted the offering and the offering closed on Feb 2nd. This is exactly the scenario depicted in the above and its accomplished by trading inside information and using multiple hedge funds to bypass the sec rule that prevents funds from shorting before an offering they participate in. Then these funds can wash trade the stock price lower trading back and forth between each other, to make even more money shorting the stock. You can see how many naked shares that remained uncovered by the 2nd of Feb.

20240202|829392604|SINT|5,939,951|SINTX TECHNOLOGIES INC COM COM|0.15

Something posted by XenaLives years ago and it seems to correlate with all this, especially post split as theyve been walking the price down.

The 10000 can be wash traded back and forth freely between colluding computers. Tons of money is made so they can now walk the stock down even lower because risk has been reduced.
Instead of thinking of this as simply colluding computers, think of it as Fund A & Fund B colluding to trade back n forth to walk the price down. Anson and the other funds in the family are well known for this sort of behavior and they couldnt have been more obvious about it after the Feb 2023 offering.

Quote Sources:
https://web.archive.org/web/20190331202955/https://www.bloomberg.com/opinion/articles/2015-06-03/insider-traders-made-some-easy-money-on-stock-offerings
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173751723
https://investorshub.advfn.com/boards/replies.aspx?msg=173751723
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=139777542

Technically true but what's more needed than a continuance of the ceo's salary + his well earned annual bonus? Trust me, he won't forego his paycheck, even if it so-hurts him (as I'm sure, always) to let down his trusting minions.
so the shares can be distributed on an as needed basis overtime?
As a side note, Sonny needs to get the word out more. Only 4k traded so far. Seems like no one but us on IHUb and ST knows Sint is even alive. Go Sonny! Get that pr engine running....

Correct me if im wrong, but isnt the offering is an ATM, so the shares can be distributed on an as needed basis overtime? They dont need to lower the price to generate interest necessarily, very undervalued as it is at only $4m marketcap (~750k x $5.3) which is less than stockholder equity. Actually they need news to help support the stockprice when they distribute especially if the goal is to dilute the conspiracy of funds.
As always Joe, your post is angled as a basher post like youre part of that wolfpack.

he alleged target was publicly traded Catalyst subsidiary Callidus Capital Corp., claims the lawsuit, which dubs the Anson, West Face and several associated and unrelated individuals as “Wolfpack Conspirators.”

https://financialpost.com/news/fp-street/catalyst-capital-files-450-million-lawsuit-accusing-anson-funds-west-face-of-short-selling-conspiracy

========================================

Section 2 - List of Funds Connected to this Wolfpack of Funds

The following will show there has in fact been a conspiracy of funds, shorting and distorting SINT & Sintx for the past 9 years. My next post will give some insight into how this family of funds might operate. A third post will show that they target vulnerable but promising companies with valuable assets they can secure significant profits from, just how valuable Sintx IP could be, and methods used to defend Sintx from this conspiracy of funds.
Its worth noting that 3 of the family of funds appear to be accumulating a position, just like what was done to Nano in its lawsuit against this conspiracy of funds. Which means they could be getting ready to make their move. Look how it accumulated its position in Nano and then realize three of its family of hedge funds is currently accumulating positions: Anson Funds Management LP, L1 Capital Global Opportunities Master Fund, Ltd. , Lind Global Fund II LP .



https://i.imgur.com/gRnIWov.jpeg

Conspiracy of Funds

First off lets establish the conspiracy of funds working together. Fortunately, in another unrelated lawsuit, the list has been provided:

Plaintiff further asserts that many of the potential investors that it contacted on behalf of Defendant operate as a family of hedge funds, all managed by the same investment advisor.

List of potential investors the Plaintiff was referencing. All the funds that seem to be connected are in red.

List named the following:
Anson Funds Management LP and its affiliates
Ayrton Capital, Altos Opportunity Fund and their
affiliates
Crede Capital Group, Acquitas Capital and its affiliates
CVI Investment, Heights Management, SIG and their
affiliates
Connective Capital and its affiliates
Empery Asset Management and its affiliates
Intracoastal Capital LP and its affiliates
Hudson Bay Capital Management and its affiliates
Ionic Venture LLC and its affiliates
Lind Partners and its affiliates
Li Capital Global Opportunities Master Fund and their
affiliates
Sabby Management LLC and its affiliates

https://images.law.com/contrib/content/uploads/documents/404/140289/51-2023-08-31-043-Order-Denying-SJMotion.pdf

History of those Funds stake in AMDA/SINT since 2015

List of Funds that have had stakes in AMDA/SINT at one time or another. The first three listed could be accumulating positions in SINT like what was done to NANO. These three funds are connected.

4/01/2024 L1 Capital Global Opportunities Master Fund, Ltd.
https://www.sec.gov/Archives/edgar/data/1269026/000107997324000472/0001079973-24-000472-index.htm

2024-05-14 13F Anson Funds Management LP 959,297 47
https://fintel.io/so/us/sint

2/07/24 Lind Global Fund II LP
https://www.sec.gov/Archives/edgar/data/1269026/000092963824000396/0000929638-24-000396-index.htm

2/16/2023 INTRACOASTAL CAPITAL, LLC
https://www.sec.gov/Archives/edgar/data/1269026/000121390023012455/0001213900-23-012455-index.htm

2/14/2023 Lind Global Fund II LP
https://www.sec.gov/Archives/edgar/data/1269026/000092963823000614/0000929638-23-000614-index.htm

05/18/2018 CVI Investments, Inc.
https://www.sec.gov/Archives/edgar/data/1269026/000110465918034362/0001104659-18-034362-index.htm

01/19/2017 SABBY MANAGEMENT, LLC
https://www.sec.gov/Archives/edgar/data/1269026/000153561017000068/0001535610-17-000068-index.htm

07/14/2016 ALPHA CAPITAL ANSTALT
https://www.sec.gov/Archives/edgar/data/1269026/000121390016014963/0001213900-16-014963-index.htm

9/14/2015 Frigate Ventures LP = Anson Group
This Schedule 13G (this “Schedule 13G”) is being filed on behalf of Frigate Ventures LP (d/b/a Anson Group), a Texas limited partnership (“Frigate”), Admiralty Advisors LLC, a Texas limited liability company (“Admiralty”), Mr. Bruce R. Winson, the principal of Frigate and Admiralty, M5V Advisors Inc. (d/b/a Anson Group Canada), an Ontario, Canada corporation (“M5V”), Mr. Adam Spears, a director of M5V, and Mr. Moez Kassam, a director of M5V, relating to Common Stock, $.01 par value (the “Common Stock”), of Amedica Corporation, a Delaware corporation (the “Issuer”).
https://www.sec.gov/Archives/edgar/data/1269026/000119312515319457/0001193125-15-319457-index.htm

Hudson Bay Capital Management LP 2,789,867 2.16 870,438 Sep 30, 2015
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=118775462


XenaLives connecting CVI to ALPHA CAPITAL ANSTALT
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143618825


Lawsuit Sources:
https://www.sec.gov/Archives/edgar/data/1491072/000119312523131774/d264274dex993.htm
https://images.law.com/contrib/content/uploads/documents/404/140289/51-2023-08-31-043-Order-Denying-SJMotion.pdf

This case connects additional funds to Anson that have not had a stake in SINT in the past like Empery Asset Management.
https://casetext.com/case/augenbaum-v-anson-invs-master-fund-8

========================================

Section 3 - A conspiracy of shorting and distorting.

This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174696175

According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as its been after Sintx IP for going on a decade. The following post goes into how much the company should be valued, methods used to protect IP, and sheer product addressable market size of over $320 billion.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174725108

Re Bal's latest: looking at pre-market volume of 14, along with a somewhat stagnant trading pattern since the announcement, I'm guessing once again, few are willing to support at this price, Bal's all too familiar routine....but...time is ticking! I fully expect another announcement shortly, along with a nice price drop, in order to lure them in. He may first do a repeat of the past offer (in case no one really heard lol), but yeah, this is the way he'll go. Actual price when they're able to get enough cash? Under 4....My opinion of course.

Remember folks: if management doesn't see it as investment-worthy, why should you?

if the 24/7 clown is predicting war and promoting fake products. You can be 100% sure he is wrong. He has never been right about anything. He is a useful idiot
Lets see, i said that Sintx was getting ready to sell itself and it sold part of itself. That part was right. I said Zimmer was its strategic partner, that was right too. I even said Zimmer wanted to acquire Sintx...that was at least true at one time if not still true. I said there was a conspiracy here and sure enough there has been a short and distort conspiracy manipulating the stock for the past 9 years. While i havent proven it, there is even evidence to suggest that conspiracy of funds was trying to take over Sintx through hostile means as they have done this in regards to other companies as ive claimed before. The CEO of Sintx has been deploying multiple methods to prevent hostile takeovers, and the IP is very valuable...something i knew/said to be true back in 2015 before i understood much about the tech.
I predicted Pernix bankruptcy, 2 years later it went BK. I said EM radiation was causing Teslas to go out of control well before there was much evidence to back that claim, thats true. I said Tesla was a scam and sure enough its being investigated for such actions.

Something i have predicted that has not come true...yet, is a global depression. Course global war could help keep that from happening. Multiple predictions have come to pass but few come when i think they will.
I mostly proved that 911 happened so the US had legal grounds to leave the 1972 Anti-ballistic treaty so SpaceX could be born (began the same month US officially left the treaty), and launch Brilliant Pebbles/Eyes into Orbit. The US was about to violate the treaty with the programs Bush Jr was pushing had 911 not occurred. I even found proof that flying saucers are not only real, but are in fact manmade. First invented in the 1930s and further developed by the Nazi's when they seized Viktor Schauberger.

TA, you are part of that short and distort conspiracy, directly or indirectly, and you show it with every lie you post. Odd out of all of the accounts, you rarely speak truth. Least the others that bash Sintx intermix truth in their posts. Useful idiot might be the only thing true in what you said.

========================================

Section 2 - Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn

Total = $324.36bn

========================================

Section 3 - A conspiracy of shorting and distorting.

This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174693152

This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174696175

According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as its been after Sintx IP for going on a decade. The following post goes into how much the company should be valued, methods used to protect IP, and sheer product addressable market size of over $320 billion.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174725108

========================================

Section 4 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

I don't see red or blue.
I see neither red nor blue.
Either one of these is correct.
Can't you get ANYTHING right, bozo?

I dont see red nor blue i see purple. This isnt a political debate, its looking at the signs. Arms buildup means war. That in itself doesnt have anything to do with Trump other than his policies during his last administration opened that up as did his US first policies. However Trump being president means the US is far more likely to get into war because people would rather have a leader they see as strong, which the recent "attempt on his life" is being spun to increase that image, than frail. Recent debate was spun to to make Biden look weaker.
I laid out facts for you in my last post and you ignored them. Trump intends on removing illegal and deploying the military within the US, including camps to house those illegals. Those are all Hitler like policies and deploying military into US cities sets up dangerous precedents/possibilities.
The Supreme court just set it up for future presidents to be allowed to pursue illegal actions on behalf of the country without any fear of legal consequences. That allows for dictatorial behaviors by any future President and Trumps definitely the type to utilize these as its well known his public persona is an admirer of Hitler.

Theres been war somewhere in the world during every presidency. US is not active in Ukraine nor in Israel. We are simply sending aid. When i said Trump = War, i mean US involved war. I see WW3 as more likely under Trump than Biden certainly, but i could see a war within with Trump return to presidency and Civil War if Biden was re-elected. All that is good for Sintx Armor and greater need for ortho implants, wound care, anti-infective products, etc... which is all good for Sintx.

Its also estimated that China will take Taiwan during the next presidency.

========================================

Section 2 - Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn

Total = $324.36bn

========================================

A conspiracy of shorting and distorting.

This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174693152

This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174696175

According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as its been after Sintx IP for going on a decade. The following post goes into how much the company should be valued, methods used to protect IP, and sheer product addressable market size of over $320 billion.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174725108

Don't want to get political but everything political seems to thrive on fear, fear, fear. Regardless one's political views (like stocks), we should stick to facts. Under the previous administration, no wars. Two going on today, along with billions being drained and unaccountable for (and apparently no end in sight) via the Russian-Ukraine conflict.

You stated there WILL be war under Trump but failed to state there IS war under Biden.

To carry out a deportation operation designed to remove more than 11 million people from the country, Trump told me, he would be willing to build migrant detention camps and deploy the U.S. military, both at the border and inland.
He would gut the U.S. civil service, deploy the National Guard to American cities as he sees fit
Thats more of a war within than outside but i expect China to take Taiwan which the US has been preparing for since Trumps first administration. Trump means war and thats good for Sintx Armor and its partner NP Aerospace! Despite the emphasis that doesnt thrill me at all nor does Hitler 2.0 indicated in that article.

In a historic announcement, in May 2020, TSMC shared its plans to invest $12B in Phoenix, Arizona

https://time.com/6972021/donald-trump-2024-election-interview/

The world wasn’t ready for Trump in 2016. It’s not making that mistake this time.

America’s NATO allies are ramping up weapons production, consulting Donald Trump’s advisers and holding secret meetings with each other to feverishly lay the groundwork for his return.

https://www.politico.com/news/2024/07/07/nato-prepare-trump-2024-00165522

========================================

Section 2 - Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn

Total = $324.36bn

========================================

Section 3 - A conspiracy of shorting and distorting.

This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174693152

This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174696175

According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as its been after Sintx IP for going on a decade. The following post goes into how much the company should be valued, methods used to protect IP, and sheer product addressable market size of over $320 billion.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174725108

Another opinion, spoken as fact. Sigh.....Reminds me of the idea that Sint is really a good investment even though it continues to reverse and dilute.
Trump presidency means War...

Trump presidency means War and that'll be good for Sintx Armor and its partner NP Aerospace.

“Already one of the most iconic photographs in American history—and one that I suspect will propel Donald Trump back to the White House,” British journalist Piers Morgan wrote on X.

========================================

Section 3 - Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn

Total = $324.36bn

========================================

A conspiracy of shorting and distorting.

This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174693152

This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174696175

According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as its been after Sintx IP for going on a decade. The following post goes into how much the company should be valued, methods used to protect IP, and sheer product addressable market size of over $320 billion.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174725108

ANY small bump or sign after a potential run is quashed by Dipwad Sonny….. why is that?????
I'd argue that the hedge funds knew the filing was coming and thats why there was sudden uptick in basher posts on cafepharma and here. Likely building up the naked shorts before offering as was done all of the 2023 into 2024 offerings.

https://stocktwits.com/NoneYaBiz61/message/579451246

pumps sintx in Zimmer forums that Sintx is about to or in the middle of diluting shareholders via offerings and or reverse splits
As my posts were in response to these posts on cafepharma, its actually the opposite. That bashers increase posting before offerings and thus i respond. This shows they have access to inside information. Now if there has been an increase in naked shorts this past week then we'll know for sure as thats how the conspiracy of funds operate with their outside help...all part of their "wolfpack".

The alleged target was publicly traded Catalyst subsidiary Callidus Capital Corp., claims the lawsuit, which dubs the Anson, West Face and several associated and unrelated individuals as “Wolfpack Conspirators.”
https://financialpost.com/news/fp-street/catalyst-capital-files-450-million-lawsuit-accusing-anson-funds-west-face-of-short-selling-conspiracy

========================================

A conspiracy of shorting and distorting.

This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174693152

This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174696175

According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as its been after Sintx IP for going on a decade. The following post goes into how much the company should be valued, methods used to protect IP, and sheer product addressable market size of over $320 billion.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174725108

========================================

Section 4 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

3 Colorado poultry workers test presumptively positive for bird flu

Three poultry workers from a farm in northeast Colorado are suspected to have contracted bird flu, state and federal health officials announced Friday.

The three tested presumptively positive for H5N1, also known as avian influenza, while working at a "commercial egg layer operation," the Colorado Department of Public Health and Environment said in a statement.

They were culling poultry at the farm when they showed mild symptoms, including pink eye and common respiratory infections, the agency said. None required hospitalization.

Specimens have been sent to the U.S. Centers for Disease Control and Prevention for confirmatory testing.

The CDC said that the three worked "at a poultry facility experiencing an outbreak of the H5N1 virus that is circulating in wild birds and has been causing multistate outbreaks in dairy cows and poultry."

There have been four confirmed human cases of bird flu in the U.S. since March, all in farmworkers, with two in Michigan, one in Texas and one in Colorado, the CDC said.
https://www.cbsnews.com/news/3-colorado-poultry-workers-test-presumptively-positive-bird-flu-h5n1/

========================================

Section 2 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

========================================

Section 3 - Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn

Total = $324.36bn

========================================

Section 4 - A conspiracy of shorting and distorting.

This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174693152

This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174696175

According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as its been after Sintx IP for going on a decade. The following post goes into how much the company should be valued, methods used to protect IP, and sheer product addressable market size of over $320 billion.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174725108

Lol, well I got 3 of you now telling me the same thing......
but I do question my sanity going back and forth with you....

I thought you said Zimmer Biomet wasnt their femoral head strategic partner? That companies like Zimmer just donate their IP for other companies studies just because? Or were you gaslighting me back then?

Proof Zimmer Biomet is one of Sintx strategic partners:

Sintx 2016 10k

Together with a strategic partner, we have initiated biomechanical testing of our solid silicon nitride femoral heads. The results of this test will be released in 2017
This quote indicates the results of testing of their femoral head with a strategic partner will be released in 2017.
Those results were released testing Sintx Femoral head against Biomet's E1 liners. Thus Zimmer Biomet, or any of its subsidiaries, is Sintx strategic partner in this testing.

Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research
These are risk-averse companies that look to smaller companies like us to develop an idea, uh, and, uh, de-risk it, so to speak, and then buy that technology.


AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.

What are strategic alliances?

Strategic alliances, also known as strategic partnerships, are long-term, multi-department commitments with clearly defined goals for both companies. They differ from acquisitions and joint ventures because the companies remain separate entities (like how Starbucks and Target work together, within their own boundaries). However, strategic alliances have been known to lay the groundwork for acquisitions. But more on that later.

Quote Sources:


2016 10-k pg 13: https://www.sec.gov/Archives/edgar/data/1269026/000149315217010752/form10-k.htm
2017 results: https://ir.sintx.com/news-events/press-releases/detail/95/amedica-announces-results-of-independent-femoral-head-wear
https://web.archive.org/web/20240408152758/https://sintx.com/wp-content/uploads/2021/03/Investor-Call-Transcript-033021.pdf
https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1
https://insider.crossbeam.com/resources/strategic-alliance-definition-types-examples

Dude just give it a rest and let the dunce yell into the abyss

You understand that what im saying is investors can get a return on investment here if Sonny successfully defends Sintx from the conspiracy of hedge funds trying to steal the IP. Not to mention they could see greater return than if that conspiracy of funds won. Especially if he sells the core IP to Zimmer Biomet in the end. This falls under the debate of Stakeholder vs shareholder and how CEOs have a greater duty to their stakeholders than shareholders (alot of shareholders are stakeholders but not all).
Until then long investors can keep watching, buying any shareholder rights offerings to help protect their investment, and swing trade until Sonny wins as theres continued risk as long as those funds are trying to steal the tech. Just requires patience. The IP is destined for greatness and will help improve alot of lives! I know thats a rhetorical statement but according to the study in Section 3 of this post, it actually is destined for greatness.
The reason they can see a return is the sheer value Sonny has created with the companies IP that just needs to be commercialized with some of the partners already in place.

These are risk-averse companies that look to smaller companies like us to develop an idea, uh, and, uh, de-risk it, so to speak, and then buy that technology.
https://web.archive.org/web/20240408152758/https://sintx.com/wp-content/uploads/2021/03/Investor-Call-Transcript-033021.pdf

========================================

Section 2 - A conspiracy of shorting and distorting.

This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174693152

This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174696175

According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as its been after Sintx IP for going on a decade. The following post goes into how much the company should be valued, methods used to protect IP, and sheer product addressable market size of over $320 billion.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174725108

========================================

Section 3 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

As far as keeping the Anson types at bay, I know others have done a much better job as evidenced by less dilution and reversing. I don't know enough about how they do it. I do know they're not all the same and it's quite obvious by the numerous solicitations Mick received, that all are not necessarily interested in the products offered, just the green they can receive by ripping them and the shareholders off.

As for the spinach comparison, investors first and foremost, generally want to see a return on their 'investment', not one loss after the other. I'd rather be part of a spinach campaign that benefits me once in a while, than a "win, win mega millions for everyone and blessings for all to boot" campaign, when in reality, the only winners remain the gamers and the elite. And feel free to believe I consider management 'elite' in this case, because I do, since there are no negative repercussions whatsoever to them, for the stupid and ridiculous way they have run this thing. Evidence? The nonstop negative stock performance, going on for years, REALLY does tell the story. As mentioned in other posts, I've never personally seen a legitimate management team remain, under such a scenario. With Sint, you basically have an autocrat doing everything which is another red flag: no accountability to anyone: never an open forum with the investment community: false and misleading news releases.

And no I'm not that dumb, but I do question my sanity going back and forth with you. In case you hadn't noticed (but I'm sure you did), I ended the statement you quoted with the part you chose not to. Thus I clarified something even the dumbest amongst us could understand i.e. a stock ALWAYS down, is not worth the effort to search out further.
Only a negative direction continually, tells enough of the story to me....

Over on ST in typical basher fashion, tech01 uses a mix of truth and deception. More on the short and distort campaign being waged against Sintx in section 3 of this post.

SINTX Armor is a joke... they announced they were expecting revenue in 2022, and then again in 2023.
Then this happened....
So => 3 years with no revenue for armor.....execution failure....
Only problem is Sintx armor didnt become operational until Feb 2023 so how could they generate revenue in 2022? Also despite the setback with the furnace, they have successfully tested vehicle & body amror for production. It didnt indicate when that would occur, but by Q4 the new furnance is supposed to be in place.

SINTX Armor is expected to begin production of a competitively priced body- and vehicle-protective armor product that has undergone successful testing.

Source info:
https://stocktwits.com/Tech01/message/579198810
https://ir.sintx.com/news-events/press-releases/detail/214/sintx-technologies-announces-its-new-utah-armor-facility-is
https://ir.sintx.com/news-events/press-releases/detail/233/sintx-technologies-to-explore-strategic-opportunities

========================================

Section 2 - Renaissance Tech holdings prior to Anson/Frigate & Hudson Bay:

In regards to my post about Renaissance Tech shares in before Anson, fintel shows it earliest stake was Q4 '14. It sold that position in Q1 but was back Q2'15.

2015-02-13 13F Renaissance Technologies Llc 13,661
https://fintel.io/so/us/sint?d=2014-12-31

Renaissance Technologies, LLC 458,498 0.36 143,051 Sep 30, 2015
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=118775462

========================================

Section 3 - A conspiracy of shorting and distorting.

This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174693152

This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174696175

According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as its been after Sintx IP for going on a decade. The following post goes into how much the company should be valued, methods used to protect IP, and sheer product addressable market size of over $320 billion.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174725108

========================================

Section 4 - Reply to Joev2,

We already knew they needed money and the offering would have to close July/August timeframe to keep operations going. I expected more but then again it makes sense for them to slowly raise the OS as they need to keep the price over $1. Incidentally if Ansons group of funds have been preshorting this they'll have to buy shares off the market to cover as the ATM is direct to market. Good time to run the price up (wishful thinking). OS appears to be around 748k shares now up from 709K post split.

In regards to Mick Wynhoff's company, yet again, you chose a horrible comparison. Its like comparing growing spinach (Mick Wynhoff company) to almond trees (Sintx). Medtech takes alot of capital for R&D, water treatment does not. Very different fields hence youre using growing spinach (how Wynoff managed to avoid toxic financiers like Anson) as an example compared to growing almonds (Develop tech for use in markets that exceed hundreds of billions in size) just doesnt cut it. Spinach is very easy to grow and takes limited investment just so you know. Also who the F would want a water treatment company outside of maybe harvesting some tax loss? How likely is it the Ansons of the world would even want their properitary blend of chemicals for treating pools?

I have SEEN filings with conditions such as a clause stating the lender/ buyer could NOT sell shares for a certain period of time
Ive seen this clause used for Sintx offerings before but doesnt naked shorting and covering those naked shorts with converted warrants circumvent that?

The only evidence I personally need is the stock price as to how the CEO or company is performing.
Thats about the dumbest thing i think you have ever posted Joe. That means when Theranos, or any scam stock is flying high on the markets, its all you need to know about the company. Buys lots of shares of scam stocks being pumped. Come on we both know youre smarter than that. That cant be a honest statement on your part.

TA, you are deceptive as always. I said on June 7th that an offering needed to close July/August timeframe. Just expected a S1 offering instead of part of the shelf offering.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174564223

Well that didn't take long. Here's the best part, Boston!
You will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. Crooks! (IMHO of course)

I had personally spoken to Mick numerous times and he volunteered the info regarding gamers such as Maxim without naming any particular one. I'm only replying as a courtesy because I don't expect you to believe me anyway, and besides it's technically only hearsay. Fact is though, he never did go the route of convertibles and apparently started his tenure with about 30 million outstanding and ended it about 8 years later at 67 million.

As far as what Sonny could do or could have done is simple: do business with a lender that was more favorable to the shareholders. I have SEEN filings with conditions such as a clause stating the lender/ buyer could NOT sell shares for a certain period of time. This clearly prevents the Anson types from taking an advantage, right out the gate. Nothing more to say. I am not going to look for documents all over the place, trying to prove a point to you. It is what it is. Doesn't matter to me whether or not you believe me. I know what I am saying is true and I have no reason to make it up. I'm not trading Sint, shorting it or investing in it. I don't like the company based mostly on management and that hasn't changed for as long as I've been on this board. The only evidence I personally need is the stock price as to how the CEO or company is performing. Only a negative direction continually, tells enough of the story to me....

From another poster on the Pfsd board:
Mick and Mike brought the company to Racine, WI on June 4, 2004. It had 30,299,000 shares outstanding at 6-30-04 FY yearend and had sales of just 61,703 for that year. Mick left in Oct 2011. For the 7 1/4 years he ran the place ending on 9-30-11 shares o/s increased to 67,857,000 and the company lost 2.9 million or an average of 399K per year.
One last thing concerning Pfsd: although the company had sales of 61k in Mick's first year, they ended up with over a million rev per year. Problem with small companies is getting out of the debt hole. However, unlike Sonny, Mick made sure shareholders would not get crushed. Unfortunately with Pfsd as with many others, they just couldn't ever sustain a profit.

Ansons conspiracy of funds couldnt target every company with promising products. It would need to see certain risk reward type scenarios or if its as i suspect, they work as a front for other companies. I havent connected Renaissance to say Hudson Bay for instance, but if there is then Ansons conspiracy of funds could be working for Renaissance and thus in J&J interests. Thats just an example because i read that Ansons was given a small fine to protect some Blue Chip companies of which J&J is definitely one. And Renaissance has been shorting here since before Anson the other family funds showed up.

The minor nature of the infraction and the small size of the settlement was far from the grand hype that surrounded the investigation, which was said to involve dozens of short sellers, and numerous companies, including some blue-chip names. One fund manager called the SEC settlement with Anson “a consolation prize for some ticky tack bullshit.”

Ok. you named dropped Mick Wynoff. Could you give some information how hes relevant to this discussion? Like how he defended his company and protected its shareholders from this conspiracy of funds?

All the evidence against Maxim? There isnt alot of evidence against them but they certainly should have been aware that there was a family of funds connected to Anson fund that work together to manipulate companies like Sintx. As to if Maxim works with them in any capacity, i do not know? They provide placement services as well as market making services. We know they have at least failed to report some of the shit Ansons group of funds do. If theres any impropriety there, i again do not know? Be interested in finding out however. Now that ive disclosed all this is Sonny still working with Maxim? Its Ascendiant Capital that its working with atm. What Sonny does moving forward will give us some clue. However the shelf offering is still registered with Maxim providing placement services for that.

You dont lay any actual evidence down. You merely claim something is this way or that way. Like claiming theres no conspiracy here and using sarcasm to downplay the likelihood that there were any hostile funds trying to takeover Sintx. Post some evidence. Like what could Sonny do to protect Sintx IP and its shareholders at the same time? If you actually gave examples it would show some ineptitude on his part in regards to public markets.

========================================

A conspiracy of shorting and distorting.

This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174693152

This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174696175

According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as its been after Sintx IP for going on a decade. The following post goes into how much the company should be valued, methods used to protect IP, and sheer product addressable market size of over $320 billion.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174725108

========================================

Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm

What about the evidence that Anson types can't play the same way with every company that has promising products?
What about the evidence that "informed" CEOs (such as Mick Wynhoff) aren't easily played like "uninformed" ones (such as Bal, assuming he is only uninformed) and therefore are able to keep the o/s pretty much at bay, rather than diluting and reversing continually?
What about the evidence that given ALL the information out there concerning Maxim already, Sonny (unlike those who have learned) continues doing business 'as usual' with them, as if nothing is amiss; thereby being the real enabler of the shorts, hedge funds and gamers?

So you claim I use disinformation techniques and I likewise claim, you ignore any evidence that doesn't fit your preconceived narrative.

No need to waste a post replying. According to some, I'm one of the rare ones that bothers reading them anyway. And if true, why would that be, considering the company has been building shareholder value (according to you) while the stock price has gone down from over a million to $5 per share?

You continue to claim things to be one way yet little evidence to support it. Also, you continue to employ disinformation techniques in your posts to try to steer the conversation away from actual evidence. Im sure you'd love it if i spent my limited 3 posts here focused on you or anything else not of relevance.
Keep posting Boston. In this way, you can continue confirming to yourself that you alone, are correct; you alone know the reasons why Sint (with Bal as CEO) is a winner, despite evidence proving otherwise time and time again.
Obviously Anson and that conspiracy of hedgefunds agrees with me that Sintx Si3N4 IP is very valuable which is why they are trying to get the company and continue to attack the stockprice.

According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as this group has been after Sintx IP for going on a decade. If this group cannot get the IP through hostile means, its going to limit Sintx ability to raise funds through the marketplace to push them to sell or into bankruptcy. Sonny has successfully employed various means to prevent hostile takeovers so far. Market side is Sintx biggest weakness however and thus it needs one of its major partners like Zimmer Biomet to step up. This is why i believe its exploring its strategic options.

Their playbook is simple: they find a promising company like Nano that has attracted significant investment, furtively acquire a large position, and then seek to dismantle the company and distribute its cash for Defendants’ own benefit.
https://www.sec.gov/Archives/edgar/data/1491072/000119312523131774/d264274dex993.htm

https://fastercapital.com/content/Securities-fraud--How-ShortandDistort-Undermines-Market-Integrity.html#How-ShortandDistort-Schemes-Operate-
https://www.ethosdebate.com/lies-rhetoric-4-18-rules-disinformation/

========================================

A conspiracy of shorting and distorting.

This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174693152

This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174696175

According to this lawsuit, Anson and its related funds go after companies with valuable assets... This explains why SINT is so undervalued as its been after Sintx IP for going on a decade. The following post goes into how much the company should be valued, methods used to protect IP, and sheer product addressable market size of over $320 billion.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174725108

=======================================

Here are all the anti-takeover provisions employed at Sintx.

1. Poison pill aka Shareholder Rights Plan

2. Staggered Board

3. Shark Repellant - requiring supermajority vote

4. Golden Parachute for management

5. Crown Jewel Defense - CTL has first rights to acquire Sintx IP.

6. CTL is setup as a White Knight via its first rights to acquire Sintx IP.

7. If Sintx sold its main IP to CTL thats effectively scorched earth as Sintx has little value, in comparison, without its patent portfolio. Sintx would still have TA&T & Sintx Armor for value in the event it had to sell its core Si3n4 IP to CTL, even if for a short time.

========================================

Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm